Restriction endonuclease isoschizomers ItaI, BsoFI and Fsp4HI are characterised by differences in their sensitivities to CpG methylation
Restriction endonuclease isoschizomers ItaI, BsoFI and Fsp4HI are characterised by differences in their sensitivities to CpG methylationB. H. Ramsahoye*, A. K. Burnett and C. Taylor1
Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, UK and 1Bristol Heart Institute, Bristol Royal Infirmary, University of Bristol, Bristol, UK
Received June 13, 1997;Accepted June 24, 1997
ABSTRACT
BsoFI, ItaI and Fsp4HI are isoshizomers of Fnu4HI (5'-GC <=> NGC-3'). Both Fnu4HI and BsoFI have previously been shown to be inhibited by cytosine-specific methylation within the recognition sequence. Fnu4HI is inhibited if either the internal cytosine at position 2 or the external cytosine at position 5 of the restriction sequence is methylated, but the precise nature of the methylation sensitivity of BsoFI is unclear from the literature. The methylation sensitivities of ItaI and Fsp4HI have not previously been reported. By methylating the plasmid pUC18 with M.SssI (a DNA cytosine-5'-methyltransferase with a specificity for CpG), we have determined that ItaI is sensitive only to methylation of internal CpG sites within the restriction sequence. The methylation sensitivity of Fsp4HI is identical to that of Fnu4HI, being inhibited by methylation of either internal CpG sites or overlapping CpG sites. BsoFI, like the other isoschizomers tested, is sensitive to a combination of internal and overlapping CpG methylation. BsoFI is also sensitive to overlapping CpG methylation (in the absence of internal CpG methylation) if CpG overlap with both sides of the recognition sequence. Sites containing one overlapping CpG (in the absence of internal CpG) are cut when methylated but show marked individual variation in their rates of cleavage. Considerable variation in the rate of cleavage by BsoFI is also observed at sites containing only internal methylated CpG. Some sites are cut slowly,whilst others fail to cut even after prolonged incubation with excess of enzyme.
Restriction enzymes that cut in the sequence 5'-GCNGC-3' have been used to study 5'-d(CGG)n-3' repeats. Such repeats are unstable and are prone to expansion (1 -3 ). Expanded repeats have been described in a variety of neurological disorders, the fragile X syndrome being the best characterised. Trinucleotide repeat expansion has now been described in a number of other conditions such as Huntington's disease [5'-d(CAG)n-3'] (4 ), and myotonic dystrophy [5'-d(CAG)n-3'] (5 ,6 ). In fragile X syndrome, abnormal methylation is associated with expansion of the 5'-d(CGG)n-3' repeats in the 5' untranslated region of the FMR1 gene (3 ,7 ). This may lead to transcriptional silencing of the gene. Methylation of these repeats has been detected by genomic sequencing and the use of restriction endonucleases such as Fnu4HI. This enzyme recognises the sequence 5'-GCNGC-3' but is inhibited by methylation of either the internal cytosine at position 2 of the recognition sequence or the external cytosine at position 5 (8 ).
ItaI, BsoFI and Fsp4HI are isoschizomers of Fnu4HI and are therefore potentially useful tools in such studies (9 ). However, at present the sensitivities of ItaI and Fsp4HI to cytosine methylation are unknown. New England Biolabs (D. Robinson, NEB, unpublished observations) report that BsoFI is sensitive to overlapping CpG methylation (methylation of the external cytosine), but all possible combinations have not been studied. Conversely, a study using methylated and unmethylated pBluescript SK(+) DNA as well as oligonucleotides containing trinucleotide repeats, has shown that restriction is only inhibited by methylation if both the internal and the external cytosines within the recognition sequence are methylated (10 ).
We have studied the sensitivities of ItaI, BsoFI, Fsp4HI and Fnu4HI to cytosine-5 methylation by in vitro methylation of pUC18 DNA with the methylase SssI (a DNA cytosine-5'-methyltransferase with a specificity for CpG). The subset of 5'-GCNGC-3' sites containing an internal CpG (i.e. 5'-GCSGC-3' sites, where S = G or C) or overlapping CpG(s) (where the restriction site is flanked on the 5' side by a C and/or on the 3' side by a G), can be methylated with this enzyme. Using this system, as the CpG dinucleotide is a palindrome, methylation at position 2 on one strand of the restriction site is always accompanied by reciprocal methylation at position 3 in the complementary strand. Whilst this pattern of methylation at internal cytosines is not likely to resemble that induced by a corresponding cognate methylase (such a methylase would be likely to methylate the position 2 cytosine on both strands), it is likely to be the most frequently encountered in mammalian DNA, where the vast majority of methylcytosines occur in the sequence CpG. Therefore, the methylation sensitivities determined by this method can be applied directly to studies on mammalian DNA.
By studying the published sequence of pUC18 (GenBank accession number A02710) it has been possible to determine the exact sequences of all the cleavage sites using DNASTAR sequence analysis software (DNASTAR Inc., Fig. 2 ). Complete CpG methylation of the plasmid was confirmed by the total failure of HpaII to restrict the DNA [Fig. 1 HpaII (+) digest]. It could be determined that only methylation of internal CpG inhibited restriction by ItaI. Thus after methylation, all 5'-DGCGGCH-3' sites and 5'-DGCSGCG-3' sites could not be cleaved, but 5'-DGCWGCG-3' and 5'-CGCWGCG-3' sites were completely cleaved (D = A, T or G, W = A or T, H = A, T or C and S = G or C-the recognition sequence is underlined and potentially methylatable cytosines are emboldened). Cleavage occurred in the absence of internal CpG methylation even when the external cytosines of both strands were methylated at CpG. The findings with respect to Fnu4HI were consistent with those previously reported. Restriction was inhibited by methylation of either internal CpG or overlapping CpG. The methylation sensitivity of Fsp4HI was found to be identical to that of Fnu4HI.
REFERENCES
1 Fu, Y.-H., Kuhl, D.P.A., Pizutti, A., Pieretti, M., Sutcliffe, J.S., Richards, S., Verkerk, A.J.M.H., Holden, J.J.A., Fenwick, R.G.,Jr, Warren, S.T., et al. (1991) Cell67, 1047-1058.
2 Verkerk, A.J.M.H., Pieretti, M., Sutcliffe, J.S., Fu, Y.-H., Kuhl, D.P.A., Pizutti, A., Reiner, A., Richards, S., Victoria, M.F., Zhang, F., et al. (1991) Cell65, 905-914.
3 Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boue, J., Bertheas, M.F. and Mandel, J. (1991) Science252, 1097-1102.MEDLINE Abstract
4 The Huntington's Disease Collaborative Research Group (1993) Cell72, 971-983.
5 Brook, J.D., McCurrach, M.E., Harley, H.G., Buckler, A.J., Church, D., Aburatani, H., Hunter, K., Stanton, V.P., Thirion, J.P., Hudson, T., et al. (1992) Cell68, 799-808.MEDLINE Abstract
6 Mahadevan, M., Tsilfidis, C., Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville, C., Narang, M., Barcelo, J., O'Hoy, K., et al. (1992) Science255, 1253-1255.MEDLINE Abstract